Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Agenus issues $10mm in stock up front for 4-Antibody

Executive Summary

Agenus Inc. (immunomodulators for oncology and infectious diseases) acquired privately held 4-Antibody AG for $10mm in stock up front (approximately 3.5mm shares based on Agenus’ ten-day average) and the assumption of $1.5mm in debt. 4-Antibody is also entitled to over $40mm in earn-outs in cash or stock based on the occurrence of certain milestones, including the combined entity’s market cap exceeding various thresholds ($300mm, $750mm, and $1bn) during specific time periods, the signing of a licensing agreement for 4-Antibody’s Retrocyte Display technology on or before March 31, 2014, or a company sale.
Deal Industry
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
    • Synthesis Technologies, Production Processes
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Intra-Biotech Deal
    • Payment Includes Stock
    • Acquisition of Private Biotech
    • Includes Contract
    • Full Acquisition
    • Includes Earnout

Related Companies